8YX4 | pdb_00008yx4

Crystal Structure of SARS CoV-2 Papain-like Protease PLpro-C111S in Complex with GZNL-P31


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.28 Å
  • R-Value Free: 
    0.233 (Depositor), 0.235 (DCC) 
  • R-Value Work: 
    0.194 (Depositor), 0.204 (DCC) 
  • R-Value Observed: 
    0.196 (Depositor) 

Starting Model: experimental
View more details

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 

Created with Raphaël 2.3.0Worse 01 BetterLigand structure goodness of fit to experimental dataBest fitted A1LZ6Click on this verticalbar to view details

This is version 1.0 of the entry. See complete history


Literature

Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19.

Lu, Y.Yang, Q.Ran, T.Zhang, G.Li, W.Zhou, P.Tang, J.Dai, M.Zhong, J.Chen, H.He, P.Zhou, A.Xue, B.Chen, J.Zhang, J.Yang, S.Wu, K.Wu, X.Tang, M.Zhang, W.K.Guo, D.Chen, X.Chen, H.Shang, J.

(2024) Nat Commun 15: 10169-10169

  • DOI: https://doi.org/10.1038/s41467-024-54462-0
  • Primary Citation of Related Structures:  
    8YX2, 8YX3, 8YX4, 8YX5

  • PubMed Abstract: 

    The RNA-dependent RNA polymerase (RdRp), 3C-like protease (3CL pro ), and papain-like protease (PL pro ) are pivotal components in the viral life cycle of SARS-CoV-2, presenting as promising therapeutic targets. Currently, all FDA-approved antiviral drugs against SARS-CoV-2 are RdRp or 3CL pro inhibitors. However, the mutations causing drug resistance have been observed in RdRp and 3CL pro from SARS-CoV-2, which makes it necessary to develop antivirals with novel mechanisms. Through the application of a structure-based drug design (SBDD) approach, we discover a series of novel potent non-covalent PL pro inhibitors with remarkable in vitro potency and in vivo PK properties. The co-crystal structures of PL pro with lead compounds reveal that the residues D164 and Q269 around the S2 site are critical for improving the inhibitor's potency. The lead compound GZNL-P36 not only inhibits SARS-CoV-2 and its variants at the cellular level with EC 50 ranging from 58.2 nM to 306.2 nM, but also inhibits HCoV-NL63 and HCoV-229E with EC 50 of 81.6 nM and 2.66 μM, respectively. Oral administration of the GZNL-P36 results in significantly improved survival and notable reductions in lung viral loads and lesions in SARS-CoV-2 infection mouse model, consistent with RNA-seq data analysis. Our results indicate that PL pro inhibitors represent a promising SARS-CoV-2 therapy.


  • Organizational Affiliation

    Guangzhou National Laboratory, Guangzhou, 510005, China.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Papain-like protease nsp3316Severe acute respiratory syndrome coronavirus 2Mutation(s): 1 
Gene Names: rep1a-1b
EC: 3.4.19.12 (PDB Primary Data), 3.4.22 (PDB Primary Data)
UniProt
Find proteins for P0DTD1 (Severe acute respiratory syndrome coronavirus 2)
Explore P0DTD1 
Go to UniProtKB:  P0DTD1
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP0DTD1
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Ligands 5 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
A1LZ6 (Subject of Investigation/LOI)
Query on A1LZ6

Download Ideal Coordinates CCD File 
B [auth A]2-methyl-~{N}-[1-(1-methyl-2-oxidanylidene-benzo[cd]indol-6-yl)cyclopropyl]-5-[3-(4-methyl-4-oxidanyl-piperidin-1-yl)azetidin-1-yl]benzamide
C32 H36 N4 O3
IHUOWXQOCOSXSU-UHFFFAOYSA-N
CD
Query on CD

Download Ideal Coordinates CCD File 
G [auth A]
H [auth A]
I [auth A]
J [auth A]
K [auth A]
CADMIUM ION
Cd
WLZRMCYVCSSEQC-UHFFFAOYSA-N
GOL
Query on GOL

Download Ideal Coordinates CCD File 
C [auth A]GLYCEROL
C3 H8 O3
PEDCQBHIVMGVHV-UHFFFAOYSA-N
ZN
Query on ZN

Download Ideal Coordinates CCD File 
D [auth A],
E [auth A],
F [auth A]
ZINC ION
Zn
PTFCDOFLOPIGGS-UHFFFAOYSA-N
CL
Query on CL

Download Ideal Coordinates CCD File 
M [auth A],
N [auth A],
O [auth A]
CHLORIDE ION
Cl
VEXZGXHMUGYJMC-UHFFFAOYSA-M
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.28 Å
  • R-Value Free:  0.233 (Depositor), 0.235 (DCC) 
  • R-Value Work:  0.194 (Depositor), 0.204 (DCC) 
  • R-Value Observed: 0.196 (Depositor) 
Space Group: I 41 2 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 112.48α = 90
b = 112.48β = 90
c = 219.85γ = 90
Software Package:
Software NamePurpose
PHENIXrefinement
XDSdata scaling
autoXDSdata reduction
PHASESphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 

Created with Raphaël 2.3.0Worse 01 BetterLigand structure goodness of fit to experimental dataBest fitted A1LZ6Click on this verticalbar to view details

Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Ministry of Science and Technology (MoST, China)ChinaGZNL2023401008
Ministry of Science and Technology (MoST, China)ChinaSRPG22-002
Ministry of Science and Technology (MoST, China)ChinaSRPG22-003
National Natural Science Foundation of China (NSFC)China82170473

Revision History  (Full details and data files)

  • Version 1.0: 2024-12-04
    Type: Initial release